Physician profile
Amber Wiggins
NPI 1104551746
$4,613.97
in general payments reported to CMS, 2019-2025
8 companies · $2,498 in 2025
The $2,498 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.60 · 2023: $1,709 · 2024: $376 · 2025: $2,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,333 · Food and Beverage: $2,243 · Education: $7.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,332.77 |
| Food and Beverage | $2,243.17 |
| Education | $7.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,744.36 | 2023-2024 | Cvi Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $1,728.21 | 2025 | Acuvue |
| Bausch & Lomb Americas INC. | $725.92 | 2023-2025 | Miebo, Xiidra, Infuse |
| Tarsus Pharmaceuticals, INC. | $161.05 | 2025 | Xdemvy |
| Alcon Vision LLC | $150.00 | 2025 | Tryptyr |
| Lkc Technologies, INC. | $45.45 | 2024 | |
| Sun Pharmaceutical Industries INC. | $30.60 | 2022 | |
| Abbvie INC. | $28.38 | 2023 | Vuity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Wiggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.